211 related articles for article (PubMed ID: 37430146)
1. Long-Term Effect of Switching From an Anti-CGRP Receptor to an Anti-CGRP Ligand Antibody in Treatment-Refractory Chronic Migraine: A Prospective Real-World Analysis.
Lambru G; Caponnetto V; Hill B; Ratti S; Sacco S; Murphy M; Briscoe J; Andreou AP
Neurotherapeutics; 2023 Sep; 20(5):1284-1293. PubMed ID: 37430146
[TBL] [Abstract][Full Text] [Related]
2. Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study.
Overeem LH; Lange KS; Fitzek MP; Siebert A; Steinicke M; Triller P; Hong JB; Reuter U; Raffaelli B
Front Neurol; 2023; 14():1154420. PubMed ID: 37034092
[TBL] [Abstract][Full Text] [Related]
3. Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis.
Andreou AP; Fuccaro M; Hill B; Murphy M; Caponnetto V; Kilner R; Lambru G
J Headache Pain; 2022 Nov; 23(1):139. PubMed ID: 36333710
[TBL] [Abstract][Full Text] [Related]
4. Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study.
Overeem LH; Peikert A; Hofacker MD; Kamm K; Ruscheweyh R; Gendolla A; Raffaelli B; Reuter U; Neeb L
Cephalalgia; 2022 Apr; 42(4-5):291-301. PubMed ID: 34644203
[TBL] [Abstract][Full Text] [Related]
5. Characteristics associated with response to subcutaneously administered anti-CGRP monoclonal antibody medications in a real-world community cohort of persons living with migraine: A retrospective clinical and genetic study.
Chase BA; Semenov I; Rubin S; Meyers S; Mark A; Makhlouf T; Chirayil TT; Maraganore D; Wei J; Zheng SL; Xu J; Epshteyn A; Pham A; Frigerio R; Markopoulou K
Headache; 2024 Jan; 64(1):68-92. PubMed ID: 38071464
[TBL] [Abstract][Full Text] [Related]
6. A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine.
Saccà F; Braca S; Sansone M; Miele A; Stornaiuolo A; De Simone R; Russo CV
Headache; 2023 Jun; 63(6):788-794. PubMed ID: 37254581
[TBL] [Abstract][Full Text] [Related]
7. An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor.
Schiano di Cola F; Bolchini M; Ceccardi G; Caratozzolo S; Liberini P; Rao R; Padovani A
Eur J Neurol; 2023 Jun; 30(6):1764-1773. PubMed ID: 36856538
[TBL] [Abstract][Full Text] [Related]
8. Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.
Scheffler A; Messel O; Wurthmann S; Nsaka M; Kleinschnitz C; Glas M; Naegel S; Holle D
J Headache Pain; 2020 Jul; 21(1):84. PubMed ID: 32620151
[TBL] [Abstract][Full Text] [Related]
9. Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials.
Silberstein SD; Cohen JM; Yang R; Gandhi SK; Du E; Jann AE; Marmura MJ
J Headache Pain; 2021 Jan; 22(1):2. PubMed ID: 33413075
[TBL] [Abstract][Full Text] [Related]
10. Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients.
Curone M; Tullo V; Didier HA; Bussone G
Neurol Sci; 2022 Sep; 43(9):5759-5761. PubMed ID: 35836032
[TBL] [Abstract][Full Text] [Related]
11. Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.
De Icco R; Vaghi G; Allena M; Ghiotto N; Guaschino E; Martinelli D; Ahmad L; Corrado M; Bighiani F; Tanganelli F; Bottiroli S; Cammarota F; Sances G; Tassorelli C
J Headache Pain; 2022 Sep; 23(1):123. PubMed ID: 36115947
[TBL] [Abstract][Full Text] [Related]
12. Migraine therapeutics differentially modulate the CGRP pathway.
Bhakta M; Vuong T; Taura T; Wilson DS; Stratton JR; Mackenzie KD
Cephalalgia; 2021 Apr; 41(5):499-514. PubMed ID: 33626922
[TBL] [Abstract][Full Text] [Related]
13. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
Barbanti P; Aurilia C; Cevoli S; Egeo G; Fofi L; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Filippi M; Altamura C; Vernieri F;
Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study.
Caponnetto V; Russo A; Silvestro M; Tessitore A; De Icco R; Vaghi G; Sances G; Tassorelli C; Baraldi C; Castro FL; Guerzoni S; Prudenzano MP; Fallacara A; Gentile M; Ornello R; Onofri A; Burgalassi A; Chiarugi A; De Cesaris F; Granato A; Casalena A; De Tommaso M; Mampreso E; Merlo P; Coppola G; Battistini S; Rebecchi V; Rainero I; Sepe FN; Dalla Volta G; Sacco S; Geppetti P; Iannone LF;
CNS Drugs; 2023 Dec; 37(12):1069-1080. PubMed ID: 37999868
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
Tepper S; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein S; Winner P; Leonardi D; Mikol D; Lenz R
Lancet Neurol; 2017 Jun; 16(6):425-434. PubMed ID: 28460892
[TBL] [Abstract][Full Text] [Related]
16. Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study.
Ihara K; Ohtani S; Watanabe N; Takahashi N; Miyazaki N; Ishizuchi K; Hori S; Takemura R; Nakahara J; Takizawa T
J Headache Pain; 2023 Mar; 24(1):23. PubMed ID: 36890436
[TBL] [Abstract][Full Text] [Related]
17. Real-world experience with calcitonin gene-related peptide-targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centers.
Shibata M; Fujita K; Hoshino E; Minami K; Koizumi K; Okada S; Sakai F
BMC Neurol; 2024 Jan; 24(1):32. PubMed ID: 38238659
[TBL] [Abstract][Full Text] [Related]
18. A prospective real-world analysis of erenumab in refractory chronic migraine.
Lambru G; Hill B; Murphy M; Tylova I; Andreou AP
J Headache Pain; 2020 Jun; 21(1):61. PubMed ID: 32487102
[TBL] [Abstract][Full Text] [Related]
19. Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway.
Waliszewska-Prosół M; Martelletti P
Dent Med Probl; 2024; 61(1):9-11. PubMed ID: 38284301
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score.
Iannone LF; Fattori D; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
CNS Drugs; 2022 Feb; 36(2):191-202. PubMed ID: 35146696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
